Article Figures & Data
Figures
- FIGURE 1.
ROIs (caudate, putamen, ventral striatum, and SN) overlaid on MR–PET images in control subject and PD patient. V. = ventral.
- FIGURE 2.
Average unchanged radioligand in plasma of PD patients and controls. Mean ± SD.
- FIGURE 3.
Regional standardized uptake values (SUV) time–activity curves of 18F-FE-PE2I (mean value) in PD patients and control subjects (CS).
- FIGURE 4.
Correlation of BPND estimated with SRTM and LoganRef. Each data point represents BPND values of each subject (Supplemental Table 1 provides mean and SD).
- FIGURE 5.
Correlation of BPND estimated with WAPI (Wapi_33 min_Logan Ref) and estimated with Logan Ref. Each data point represents BPND values of each subject.
- FIGURE 6.
WAPI in control subject and 2 patients with PD at H&Y stage 1 and 1.5. Images are at level of basal ganglia (A), substantia nigra, and mid-brain coronal view (B).
- FIGURE 7.
Regional BPND values in controls and PD patients. Patient with normal DAT binding can be considered as a SWEDD (scan without evidence of dopamine deficit) *P < 0.05 (with Bonferroni correction for 4 regions examined).
Tables
- TABLE 1
Demographic and Clinical Data of Control Subjects (S01–S10) and PD Patients (P1–P10)
Subject Age (y) Sex Weight (kg) Education (y) MMSE MADRS BDI-II Disease duration (y) H&Y UPDRS motor Side LEDs S01 65 F 59 15 29 2 2 NA NA NA NA NA S02 67 M 78 17 30 0 0 NA NA NA NA NA S03 64 M 76 9 30 0 0 NA NA NA NA NA S04 50 M 77 13 29 2 3 NA NA NA NA NA S05 66 M 77 13 29 4 0 NA NA NA NA NA S06 53 M 74 12 30 2 1 NA NA NA NA NA S07 51 M 83 11 30 1 2 NA NA NA NA NA S08 57 M 101 12 28 2 1 NA NA NA NA NA S09 66 M 91 17 30 0 0 NA NA NA NA NA S10 64 M 81 17 29 3 3 NA NA NA NA NA Mean ± SD 60.3 ± 7 79.7 ± 11 13.6 ± 3 29.4 ± 1 1.6 ± 1 1.2 ± 1 P1 64 M 68 10 28 0 3 12 2 23 L 265 P2 74 M 81 10 28 8 12 0.5 1 11 R De novo P3 66 F 53 10 30 6 17 6 2 18 R 940 P4 47 M 112 12 27 4 10 4 1.5 21 R 240 P5 68 M 78 16.5 30 2 8 0.25 1 18 L De novo P6 52 M 81 12 29 2 1 0.25 1 8 R 160 P7 46 M 85 16.5 30 0 2 0.6 1 16 R 160 P8 67 M 91 16 28 1 3 2 1.5 30 R 160 P9 60 M 83 15 28 0 2 1.5 1.5 27 R 354 P10 58 M 79 22 29 6 6 4 1 17 L 510 Mean ± SD 60.2 ± 9 81.1 ± 15 14 ± 4 28.7 ± 1 2.9 ± 3 6.4 ± 5* 3.1 ± 4 1.4 18.9 ± 7 348.6 ± 268 ↵*Significantly higher than in control subjects, P < 0.05.
MMSE = Mini-Mental State Examination; MADRS = Montgomery–Åsberg Depression Ratings Scale; BDI-II = Beck Depression Inventory; Side = the clinically most affected side; LED = levodopa-equivalent doses; NA = not applicable.
Supplemental Data
Files in this Data Supplement:
Jump to section
Related Articles
Cited By...
- Imaging Dopaminergic Neurotransmission in Neurodegenerative Disorders
- Whole-Body Biodistribution and Dosimetry of the Dopamine Transporter Radioligand 18F-FE-PE2I in Human Subjects
- Optimal Acquisition Time Window and Simplified Quantification of Dopamine Transporter Availability Using 18F-FE-PE2I in Healthy Controls and Parkinson Disease Patients